Core Viewpoint - The recent share reduction plan by a significant shareholder of Weisi Medical follows a peak in the company's stock price, raising concerns about the company's future performance and investment potential [2][5]. Financial Performance - Weisi Medical's net profit for the first three quarters of 2025 increased by over 30% year-on-year, reaching 1.02 billion yuan, while revenue grew by 11.58% to 3.26 billion yuan [4]. - The company's gross margin decreased from 74.78% in 2021 to 65.45% in 2024, and net margin fell from 41.28% to 25.49% during the same period [4]. - The stock price saw a significant increase, reaching a high of 72.78 yuan in early 2026, representing a more than 2.7 times increase from the low of 19.46 yuan in September 2024 [3]. Shareholder Actions - Nanjing Zhida Venture Capital, a significant shareholder, plans to reduce its stake by up to 3%, potentially cashing out over 1.7 billion yuan [5]. - Previous reductions by Zhida Venture Capital included a sale of approximately 1.18 million shares, raising at least 52 million yuan [5]. Research and Development - Weisi Medical's R&D investment decreased by 26.15% year-on-year in the first half of 2025, totaling approximately 26.29 million yuan [7]. - The number of R&D personnel dropped from 168 to 139, a decrease of about 17% [10]. - The proportion of R&D investment relative to revenue fell from 18.58% to 12.49% [8]. Project Delays - Several IPO projects, including the "Rehabilitation Equipment Assembly and Debugging Project," have faced multiple delays, with funds being repurposed for working capital [12]. - The company reported surplus funds from completed projects, indicating challenges in project execution [12].